Showing results (131-140 of 760) with videos related to
Sort By:
Pageof 76
Cancers|December 10, 2021
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple MyelomaShih-Feng Cho, Lijie Xing, Kenneth C Anderson, et al.Nature Reviews. Cancer|July 25, 2007
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targetsTeru Hideshima, Constantine Mitsiades, Giovanni Tonon, et al.Expert Opinion on Investigational Drugs|February 22, 2014
Daratumumab granted breakthrough drug statusJacob P Laubach, Yu-Tzu Tai, Paul G Richardson, et al.Proceedings of the National Academy of Sciences of the United States of America|August 7, 2003
Proteasome inhibitors disrupt the unfolded protein response in myeloma cellsAnn-Hwee Lee, Neal N Iwakoshi, Kenneth C Anderson, et al.Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Tanespimycin as antitumor therapyMeletios-Athanassios Dimopoulos, Constantine S Mitsiades, Kenneth C Anderson, et al.Best Practice & Research. Clinical Haematology|December 12, 2007
From the bench to the bedside: emerging new treatments in multiple myelomaConstantine S Mitsiades, Patrick J Hayden, Kenneth C Anderson, et al.Hematology. American Society of Hematology. Education Program|February 20, 2015
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?Paul G Richardson, Jacob P Laubach, Nikhil C Munshi, et al.Best Practice & Research. Clinical Haematology|December 12, 2007
The malignant clone and the bone-marrow environmentKlaus Podar, Paul G Richardson, Teru Hideshima, et al.Frontiers in Oncology|November 4, 2022
Bispecific antibodies in multiple myeloma treatment: A journey in progressShih-Feng Cho, Tsung-Jang Yeh, Kenneth C Anderson, et al.Expert Review of Hematology|December 20, 2013
Future agents and treatment directions in multiple myelomaEnrique M Ocio, Constantine S Mitsiades, Robert Z Orlowski, et al.Pageof 76